Literature DB >> 20025968

Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells.

Teemu Heikkilä1, Hélder A Santos, Narendra Kumar, Dmitry Yu Murzin, Jarno Salonen, Timo Laaksonen, Leena Peltonen, Jouni Hirvonen, Vesa-Pekka Lehto.   

Abstract

Cytotoxicity of ordered mesoporous silica MCM-41 and SBA-15 microparticles (fractions between 1 and 160 microm) was determined in vitro on undifferentiated human colon carcinoma (Caco-2) cell line, considering the feasibility of using these silica-based materials in oral drug formulations. The cellular endpoints employed for assessing the effects of the MCM-41 and SBA-15 microparticles on Caco-2 were: (1) cell membrane integrity by monitoring live-cell protease activity (AFC) and by employing the flow cytometry method; (2) metabolic activity by monitoring total ATP content via luminescence assay; (3) activity of apoptotic effectors by caspase-3/7 activity assay. The generation of reactive oxygen species (ROS) was also followed, specifically the hydrogen peroxide (H(2)O(2)) and the superoxide radical (O(2)(-)). MCM-41 and SBA-15 microparticles caused cytotoxic effects on the Caco-2 cells, at most tested concentrations (0.2-14 mg/ml) and incubation times (3 and 24h). The effects on the cells included weakened cell membrane integrity, diminished cell metabolism and increased apoptotic signalling. The root cause for the cytotoxicity was heightened production of reactive oxygen species (ROS), especially the formation of the superoxide radical O(2)(-) already after 3h incubation with threshold dose 1mg/ml, apparently overwhelming the antioxidant defences and causing mitochondrial dysfunction, hence increasing the apoptotic signalling. (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20025968     DOI: 10.1016/j.ejpb.2009.12.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica.

Authors:  Ying Wang; Qinfu Zhao; Yanchen Hu; Lizhang Sun; Ling Bai; Tongying Jiang; Siling Wang
Journal:  Int J Nanomedicine       Date:  2013-10-22

2.  Theranostic mesoporous silica nanoparticles biodegrade after pro-survival drug delivery and ultrasound/magnetic resonance imaging of stem cells.

Authors:  Paul J Kempen; Sarah Greasley; Kelly A Parker; Jos L Campbell; Huan-Yu Chang; Julian R Jones; Robert Sinclair; Sanjiv S Gambhir; Jesse V Jokerst
Journal:  Theranostics       Date:  2015-03-01       Impact factor: 11.556

3.  A multifunctional bioactive material that stimulates osteogenesis and promotes the vascularization bone marrow stem cells and their resistance to bacterial infection.

Authors:  Chuang Ma; Qin Wei; Bo Cao; Xinchun Cheng; Juling Tian; Hongwei Pu; Aihemaitijiang Yusufu; Li Cao
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

Review 4.  Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer.

Authors:  Anna Watermann; Juergen Brieger
Journal:  Nanomaterials (Basel)       Date:  2017-07-22       Impact factor: 5.076

5.  Investigation of the Antibacterial Effect of Mesoporous Magnesium Carbonate.

Authors:  Ken Welch; Mushtaq Ahmad Latifzada; Sara Frykstrand; Maria Strømme
Journal:  ACS Omega       Date:  2016-11-14

6.  Oral Drug Delivery Systems Based on Ordered Mesoporous Silica Nanoparticles for Modulating the Release of Aprepitant.

Authors:  Theodora Christoforidou; Dimitra Giasafaki; Eleftherios G Andriotis; Nikolaos Bouropoulos; Nikoleta F Theodoroula; Ioannis S Vizirianakis; Theodore Steriotis; Georgia Charalambopoulou; Dimitrios G Fatouros
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

7.  Aminopropyl groups of the functionalized Mobil Crystalline Material 41 as a carrier for controlled diclofenac sodium and piroxicam delivery.

Authors:  Elham Khodaverdi; Mina Ahmadi; Hossein Kamali; Farzin Hadizadeh
Journal:  Int J Pharm Investig       Date:  2017 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.